首页> Journal of clinical oncology : official journal of the American Society of Clinical Oncology> Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.

Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.

导出 OA

翻译打印收藏纠错

第一作者： Siqing,Fu

第一单位： Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

作者： Siqing,Fu ^[1] ; Bradley R,Corr ^[2] ; Kerry,Culm-Merdek ^[3] ; Colleen,Mockbee ^[3] ; Hagop,Youssoufian ^[3] ; Robert,Stagg ^[4] ; R Wendel,Naumann ^[5] ; Robert M,Wenham ^[6] ; Rafael D,Rosengarten ^[7] ; Laura,Benjamin ^[3] ; Erika Paige,Hamilton ^[8] ; Kathleen N,Moore ^[9]

作者单位： Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. ^[1] University of Colorado Hospital, Aurora, CO. ^[2] OncXerna Therapeutics Inc, Waltham, MA. ^[3] OncoMed Pharmaceuticals Inc, Redwood City, CA. ^[4] Gynecologic Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC. ^[5] Gynecologic Oncology, Moffitt Cancer Center, Tampa, FL. ^[6] Genialis Inc, Boston, MA. ^[7] Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.;Tennessee Oncology, Nashville, TN. ^[8] Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN.;Stephenson Cancer Center at the University of Oklahoma Health Sciences, Oklahoma City, OK. ^[9]